Towards an improved serogroup B Neisseria meningitidis vaccine

Bibliography

• POLLARD AJ: Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr. Infect. Dis. J. (2004) 23(12 Suppl.):S274–S279.
   Google Scholar
• MORLEY SL, POLLARD AJ: Vaccine prevention of meningococcal disease, coming soon? Vaccine (2001) 20(5-0:666–687.
   PubMed Web of Science ®Google Scholar
• CARTWRIGHT K, NOAH N, PELTOLA H: Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6–8 October, 2000. Vaccine (2001) 19(31):4347–4356.
   Google Scholar
• POLLARD AJ, LEVIN M: Vaccines for prevention of meningococcal disease. Pediatr. Infect. Dis. J. (2000) 19(4):333–344; quiz 345.
   Google Scholar
• WORLD HEALTH ORGANISATION: Control of Epidemic Meningococcal Disease. WHO Practical guidelines. 2nd Edition. World Health Organisation (1998).
   Google Scholar
• ROSENSTEIN NE, PERKINS BA, STEPHENS DS, POPOVIC T, HUGHES JM: Meningococcal disease. N Engl. J. Med. (2001) 344(18):1378–1388.
   PubMed Web of Science ®Google Scholar
• MILLER E, SALISBURY D, RAMSAY M: Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine (2001) 20\(Suppl. 1):558–567.
   Google Scholar
• DANZIG L: Meningococcal vaccines. Pediatr. Infect. Dis. J. (2004) 23(12 Suppl.):5285–5292.
   Google Scholar
• HEALY CM, BAKER CJ: The future of meningococcal vaccines. Pediatr. Infect. Dis. J. (2005) 24(2):175–176.
   PubMed Web of Science ®Google Scholar
• GEORGES P: Update on meningococcal vaccine. Pediatr. Infect. Dis. J. (2001) 20(3):311–312.
   PubMed Web of Science ®Google Scholar
• JODAR L, FEAVERS IM, SALISBURY D, GRANOFF DM: Development of vaccines against meningococcal disease. Lancet (2002) 359(9316):1499–1508.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Annual report of the Australian Meningococcal Surveillance Programme, 2003. Commun. Dis. Intell (2004) 28(2):194–206.
   Google Scholar
• VOGEL U, FROSCH M: Mechanisms of neisserial serum resistance. MoL MicrobioL (1999) 32(6):1133–1139.
   PubMed Web of Science ®Google Scholar
• FRASCH C, ZOLLINGER W, POOLMAN J: Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev. Infect. Dis. (1985) 7(4):504–510.
   PubMedGoogle Scholar
• SCHOLTEN RJ, KUIPERS B, VALKENBURG HA et al: Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J. Med. Microbiol (1994) 41:236–243.
   PubMedGoogle Scholar
• YAKUBU D, ABADI F, PENNINGTON T: Molecular typing methods for Neisseria meningitidis. J. Med. MicrobioL (1999) 48(12):1055–1064.
   PubMed Web of Science ®Google Scholar
• YAZDANKHAH SP, LINDSTEDT BA, CAUGANT DA: Use of variable-number tandem repeats to examine genetic diversity of Neisseria meningitidis. J. Clin. Microbiol (2005) 43(01699–1705.
   PubMed Web of Science ®Google Scholar
• URWIN R, RUSSELL JE, THOMPSON EA et al.: Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect. Immun. (2004) 72(105955–5962.
   Google Scholar
• URWIN R, MAIDEN MC: Multi-locus sequence typing: a tool for global epidemiology. Trends Microbiol (2003) 11(10479–487.
   Web of Science ®Google Scholar
• MURPHY KM, O& DONNELL KA, HIGGINS AB, O'NEILL C, CAFFERKEY MT: Irish strains of Neisseria meningitidis: characterisation using multilocus sequence typing. Br. J. Biomed. Sci. (2003) 60(4):204–209.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI H, KUROKI T, WATANABE Yet al.: Characterization of Neisseria meningitidis isolates collected from 1974 to 2003 in Japan by multilocus sequence typing. J. Med. Microbiol (2004) 53(Et 7):657–662.
   Google Scholar
• KIRSCH E, BARTON P, KITCHEN L, GIROIR B: Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr. Infect. Dis. (1996) 15(11):967–979.
   Google Scholar
• POLLARD AJ, MAIDEN MCJ: Meningococcal Vaccines. Pollard AJ, Maiden MCJ (Eds), Humana Press, Totowa, New Jersey, USA (2001).
   Google Scholar
• POLLARD AJ, MOXON ER: The meningococcus tamed? Arch. Dis. Child. (2002) 87(1):13–17.
   Google Scholar
• LYSTAD A, AASEN S: The epidemiology of meningococcal disease in Norway 1975-91. NIPH Ann. (1991) 14(2):57–65.
   PubMedGoogle Scholar
• BJUNE G, HOIBY EA, GRONNESBY JK et al.: Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet (1991) 338(8775):1093–1096.
   PubMed Web of Science ®Google Scholar
• BOSLEGO J, GARCIA J, CRUZ C et aL: Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine (1995) 13(9):821–829.
   Google Scholar
• DE MORAES JC, PERKINS BA, CAMARGO MC et al.: Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet (1992) 340(8827):1074–1078.
   PubMed Web of Science ®Google Scholar
• SIERRA GV, CAMPA HC, VARCACEL NM et al.: Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. (1991) 14(2):195–207; discussion 208–110.
   Google Scholar
• POOLMAN J, LIND I, JONSDOTTIR I et al.: Meningococcal serotypes and serogroup B disease in north-west Europe. Lancet (1986) 2(8506):555–558.
   PubMed Web of Science ®Google Scholar
• BOVRE K, HOLTEN E, VIK-MO H et al.: Neisseria meningitidis infections in Northern Norway: an epidemic in 1974-1975 due mainly to group B organisms. J. Infect. Dis. (1977) 135(4):669–672.
   PubMed Web of Science ®Google Scholar
• DE MAEYER S, SEBA J, REGINSTER G: Epidemiology of meningococcal meningitis in Belgium. J. Infect. (1981) 3(1 Suppl.):63–70.
   Google Scholar
• MOCCA L, DEL REAL G, FRASCH C: Serotypes and polyacrylamide gel electrophoresis types among disease-associated isolates of group B Neisseria meningitidis in Spain 1976-1979. J. Infect. Dis. (1983) 148(2):249–253.
   PubMed Web of Science ®Google Scholar
• SEXTON K, LENNON D, OSTER P et al.: The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic. NZ Med. J. (2004) 117(1200):U1015.
   PubMedGoogle Scholar
• THOMAS M: Prevention of group B meningococcal disease by vaccination: a difficult task. NZ Med. J. (2004) 117(1200):U1016.
   PubMedGoogle Scholar
• O'HALLAHAN J, LENNON D, OSTER P: The stategy to control New Zealand's epidemic of Group B meningococcal disease. Pediatr. Infect. Dis. J. (2004) 23(12):5293–5298.
   Google Scholar
• SEXTON K, LENNON D, OSTER P et aL: Proceedings of the Meningococcal Vaccine Strategy World Health Organization satellite meeting, 10 March 2004, Auckland, New Zealand. NZMed. 1 (2004) 117(1200):1 p preceding U1027.
   Google Scholar
• ROSENSTEIN N, PERKINS B, STEPHENS D et al.: The changing epidemiology of meningococcal disease in the United States, 1992–1996.1 Infect. Dis. (1999) 180(6):1894–1901.
   Google Scholar
• WYLE FA, ARTENSTEIN MS, BRANDT BL et aL: Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis. (1972) 126(5):514–521.
   PubMed Web of Science ®Google Scholar
• FINNE J, LEINONEN M, MAKELA PH: Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet (1983) 2(8346):355–357.
   PubMed Web of Science ®Google Scholar
• DEW SJ, ZOLLINGER WD, SNOY PJ et aL: Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys. Infect. Immun. (1997) 65(3):1045–1052.
   PubMed Web of Science ®Google Scholar
• ZOLLINGER WD, MORAN EE, DEW SJ, FRASCH CE: Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Infect. Immun. (1997) 65(3):1053–1060.
   PubMed Web of Science ®Google Scholar
• JENNINGS HJ, ROY R, GAMIAN A: Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J. Immunol. (1986) 137(5):1708–1713.
   PubMed Web of Science ®Google Scholar
• JENNINGS H, GAMIAN A, ASHTON F: N-Propionylated Group B Meningococcal polysaccharide mimics a unique epitope on Group B Neisseria meningitidis. J. Exp. Med. (1987) 165:1207–1211.
   PubMed Web of Science ®Google Scholar
• ASHTON F, RYAN JA, MICHON F, JENNINGS H: Protective efficacy of mouse serum to the N-propionyl derivative of meningococcal group B polysaccharide. Microb. Pathog. (1989) 6(6):455–458.
   PubMed Web of Science ®Google Scholar
• FUSCO PC, MICHON F, TM JY, BLAKE MS: Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. Infect. Dis. (1997) 175(2):364–372.
   Google Scholar
• BRUGE J, BOUVERET-LE CAM N, DANVE B, ROUGON G, SCHULZ D: Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine (2004) 22(9-101087–1096.
   Google Scholar
• MOE GR, DAVE A, GRANOFF DM: Epitopes recognized by a nonautoreactive murine anti-N-propionyl meningococcal group B polysaccharide monoclonal antibody. Infect. Immun. (2005) 73(4):2123–2128.
   PubMed Web of Science ®Google Scholar
• GRANOFF DM, BARTOLONI A, RICCI S et al.: Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J. Immunol. (1998) 160(10):5028–5036.
   PubMed Web of Science ®Google Scholar
• MOE GR, GRANOFF DM: Molecular mimetics of Neisseria meningitidis serogroup B polysaccharide. Int. Rev. Immunol. (2001) 20(2):201–220.
   PubMedGoogle Scholar
• MOE GR, TAN S, GRANOFF DM: Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningitidis serogroup B disease. FEMS Immunol. Med. MicrobioL (1999) 26(3-4):209–226.
   PubMed Web of Science ®Google Scholar
• TAPPERO JW, LAGOS R, BALLESTEROS AM et al.: Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA (1999) 281(10:1520–1527.
   PubMedGoogle Scholar
• HOLST J, FEIRING B, NAESS LM et al.: The concept of 'tailor-made', protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine (2005) 23(17-102202–2205.
   Google Scholar
• BJUNE G, GRONNESBY JK, HOIBY EA, CLOSS O, NOKLEBY H: Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann. (1991) 14(2):125–130; discussion 130–122.
   Google Scholar
• HOLST J, FEIRING B, FUGLESANG JEet aL: Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine (2003) 21(7-8):734–737.
   PubMed Web of Science ®Google Scholar
• WEDEGE E, HOIBY EA, ROSENQVIST E, BJUNE G: Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect. Immun. (1998) 66(7):3223–3231.
   PubMed Web of Science ®Google Scholar
• BALKHY HH, MEMISH ZA, OSOBA AO: Meningococcal carriage among local inhabitants during the pilgrimage 2000-2001. Int. J. Antimicrob. Agents (2003) 21(2):107–111.
   PubMed Web of Science ®Google Scholar
• O'HALLAHAN J, LENNON D, OSTER G et al.: From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine (2005) 23(17-102197–2201.
   Google Scholar
• OSTER P, LENNON D, O'HALLAHAN J et al.: MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine (2005) 23(17–18):2191–2196.
   Google Scholar
• DYET KH, MARTIN DR: Sequence variation in the porB gene from B:P1.4 meningococci causing New Zealand's epidemic./ Clin. Microbiol (2005) 43(2):838–842.
   Google Scholar
• ROSENQVIST E, HOIBY EA, WEDEGE E et al.: Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. (1995) 63(12):4642–4652.
   PubMed Web of Science ®Google Scholar
• CARTWRIGHT K, MORRIS R, RUMKE H et al.: Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine (1999) 17(20-21):2612–2619.
   PubMed Web of Science ®Google Scholar
• DE KLEIJN ED, DE GROOT R, LABADIE J et al.: Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine (2000) 18(15):1456–1466.
   PubMed Web of Science ®Google Scholar
• VAN DER LEY P, POOLMAN JT: Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect. Immun. (1992) 60(8):3156–3161.
   PubMed Web of Science ®Google Scholar
• VAN DER LEY P, VAN DER BIEZEN J, POOLMAN JT: Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine (1995) 13(4):401–407.
   PubMed Web of Science ®Google Scholar
• MARTIN SL, BORROW R, VAN DER LEY P et al.: Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine (2000) 18(23):2476–2481.
   Google Scholar
• FUKASAWA LO, DIAS WO, SCHENKMAN RP, RAW I, TANIZAKI MM: Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice. FEMS Immunol Med. Microbiol (2004) 41(3):205–210.
   PubMed Web of Science ®Google Scholar
• HANEBERG B, DALSEG R, WEDEGE E et al.: Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect. Immun. (1998) 66(4):1334–1341.
   PubMed Web of Science ®Google Scholar
• OFTUNG F, NAESS LM, WETZLER LM et al.: Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine. Infect. Immun. (1999) 67(2):921–927.
   PubMed Web of Science ®Google Scholar
• DRABICK JJ, BRANDT BL, MORAN EEet al.: Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers. Vaccine (1999) 18(1–2):160–172.
   Google Scholar
• BAKKE H, SETEK TN, HUYNH PN et al.: Immunisation schedules for non-replicating nasal vaccines can be made simple by allowing time for development of immunological memory. Vaccine (2004) 22(17-102278–2284.
   Google Scholar
• GOLDSCHNEIDER I, GOTSCHLICH E, ARTENSTEIN MS: Human immunity to the meningococcus: II. Development of natural immunity. J. Exp. Med. (1969) 129(6):1327–1348.
   Google Scholar
• GOLDSCHNEIDER I, GOTSCHLICH E, ARTENSTEIN MS: Human immunity to the meningococcus: I. The role of humoral antibodies. J. Exp. Med. (1969) 129(6):1307–1326.
   PubMed Web of Science ®Google Scholar
• BORROW R, ANDREWS N, GOLDBLATT D, MILLER E: Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect. Immun. (2001) 69(3):1568–1573.
   PubMed Web of Science ®Google Scholar
• BORROW R, BALMER P, MILLER E: Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine (2005) 23(17-18):2222–2227.
   PubMed Web of Science ®Google Scholar
• ANTTILA M, ESKOLA J, AHMAN H, KAYHTY H: Avidity of IgG for Streptococcus pneumoniae Type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J. Infect. Dis. (1998) 177(61:1614–1621.
   PubMed Web of Science ®Google Scholar
• JOSEPH H, MILLER E, DAWSON M et al.: Meningococcal serogroup a avidity indices as a surrogate marker of priming for the induction of immunologic memory after vaccination with a meningococcal A/C conjugate vaccine in infants in the United Kingdom. J. Infect. Dis. (2001) 184(5):661–662.
   PubMed Web of Science ®Google Scholar
• RICHMOND P, BORROW R, GOLDBLATT D et al.: Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J. Infect. Dis. (2001) 183(1):160–163.
   PubMed Web of Science ®Google Scholar
• GOLDBLATT D, PINTO VAZ A, MILLER E: Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J. Infect. Dis. (1998) 177:1112–1115.
   PubMed Web of Science ®Google Scholar
• LONGWORTH E, BORROW R, GOLDBLATT D et al.: Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine (2002) 20(19-20):2592–2596.
   PubMed Web of Science ®Google Scholar
• VERMONT CL, VAN DIJKEN HH, DE GROOT R, VAN ALPHEN L, VAN DEN DOBBELSTEEN GP: PorA-specific differences in antibody avidity after vaccination with a hexavalent Men B outer membrane vesicle vaccine in toddlers and school children. Vaccine (2004) 22(23-24):3008–3013.
   PubMed Web of Science ®Google Scholar
• BALMER P, BORROW R: Serologic correlates of protection for evaluating the response to meningococcal vaccines. Expert Rev. Vaccines (2004) 3(1):77–87.
   PubMedGoogle Scholar
• ISON CA, AN WAR N, COLE MJ et al: Assessment of immune response to meningococcal disease: comparison of a whole-blood assay and the serum bactericidal assay. Microb. Pathog (1999) 27(4):207–214.
   PubMed Web of Science ®Google Scholar
• MORLEY SL, COLE MJ, ISON CA et al.: Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants. Pediatr. Infect. Dis. J. (2001) 20(11):1054–1061.
   PubMed Web of Science ®Google Scholar
• WELSCH JA, MOE GR, ROSSI R et al: Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J. Infect. Dis. (2003) 188(11):1730–1740.
   PubMed Web of Science ®Google Scholar
• SCHLESINGER M, GREENBERG R, LEVY J, KAYHTY H, LEVY R: Killing of meningococci by neutrophils: effect of vaccination on patients with complement deficiency. J. Infect. Dis. (1994) 170(2):449–453.
   PubMed Web of Science ®Google Scholar
• AASE A, HOIBY EA, MICHAELSEN TE: Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine. Scand. J. Immunol (1998) 47(0388–396.
   PubMed Web of Science ®Google Scholar
• AASE A, NAESS LM, SANDIN RH et al.: Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease. Vaccine (2003) 21(17-102042–2051.
   Google Scholar
• POOLMAN J, BERTHET FX: Alternative vaccine strategies to prevent serogroup B meningococcal diseases. Vaccine (2001) 20\(Suppl. 1):524–526.
   Google Scholar
• DANVE B, LISSOLO L, MIGNON M et al.: Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine (1993) 11(12):1214–1220.
   PubMed Web of Science ®Google Scholar
• DANVE B, CADOZ M, LISSOLO L et ell.: Safety and immunogenicity of a Neisseria meningitidis group B transferrin binding protein vaccine in adults. Eleventh International Pathogenic Neisseria Conference. Paris, France (1–6 November 1998).
   Google Scholar
• WEST D, REDDIN K, MATHESON M et al.: Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect. Immun. (2001) 69(3):1561–1567.
   PubMed Web of Science ®Google Scholar
• FERREIROS C, FERREIRO N, CRIADO MT: [Influence of adjuvants on the ability of anti-Tbp antibodies to block transferrin binding, iron uptake and growth of Neisseria meningitis]. Enferm. Infecc. Microbiol Clin. (2002) 20(7):316–320.
   PubMed Web of Science ®Google Scholar
• MARTIN D, CADIEUX N, HAMEL J, BRODEUR BR: Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J. Exp. Med. (1997) 185(7):1173–1183.
   PubMed Web of Science ®Google Scholar
• CADIEUX N, PLANTE M, RIOUX C et al: Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect. Immun. (1999) 67(9):4955–4959.
   PubMed Web of Science ®Google Scholar
• MOE GR, TAN S, GRANOFF DM: Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect. Immun. (1999) 67(11):5664–5675.
   PubMed Web of Science ®Google Scholar
• MOE GR, ZUNO-MITCHELL P, LEE SS,LUCAS AH, GRANOFF DM: Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B. Infect. Immun. (2001) 69(61:3762–3771.
   PubMed Web of Science ®Google Scholar
• MOE GR, ZUNO-MITCHELL P, HAMMOND SN, GRANOFF DM: Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect. Immun. (2002) 70(11):6021–6031.
   PubMed Web of Science ®Google Scholar
• OLIVER KJ, REDDIN KM, BRACEGIRDLE P et al: Neisseria lactamica protects against experimental meningococcal infection. Infect. Immun. (2002) 70(7):3621–3626.
   PubMed Web of Science ®Google Scholar
• GORRINGE A, HALLIWELL D, MATHESON M et al.: The development of a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Vaccine (2005) 23(17-102210–2213.
   Google Scholar
• O'DWYER CA, REDDIN K, MARTIN D et al.: Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential. Infect. Immun. (2004) 72(11):6511–6518.
   Google Scholar
• VERMONT CL, VAN DEN DOBBELSTEEN GP: Meningococcal serogroup B infections: a search for a broadly protective vaccine. Expert Rev. Vaccines (2003) 2(5):673–681.
   PubMedGoogle Scholar
• POLLARD AJ, FRASCH C: Development of natural immunity to Neisseria meningitidis. Vaccine (2001) 19(11-12):1327–1346.
   PubMed Web of Science ®Google Scholar
• BRAUN JM, BEUTH J, BLACKWELL CC et al: Neisseria meningitidis, Neisseria lactamica and Moraxella catarrhalis share cross-reactive carbohydrate antigens. Vaccine (2004) 22(7):898–908.
   PubMed Web of Science ®Google Scholar
• GRIFFISS JM, BRANDT B, GOROFF D, BAKER CJ: Immune response of infants and children to disseminated infections with Neisseria meningitidis. J. Infect. Dis. (1984) 150(1):71–79.
   PubMed Web of Science ®Google Scholar
• PLESTED JS, MAKEPEACE K, JENNINGS M et al: Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis. Infect. Immun. (1999) 67(10):5417–5426.
   PubMed Web of Science ®Google Scholar
• PLESTED JS, FERRY B, COULL PA et al.: Functional opsonic activity of human serum antibodies to inner core lipopolysaccharide (galE) of serogroup B meningococcal measured by flow cytometry. Infect. Immun. (2001) 69(5):3203–3213.
   PubMed Web of Science ®Google Scholar
• PLESTED JS, HARRIS SL, WRIGHT JC et al: Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia. J. Infect. Dis. (2003) 187(8):1223–1234.
   PubMed Web of Science ®Google Scholar
• KAHLER CM, DATTA A, TZENG Y, CARLSON RW, STEPHENS D: Inner core assembly and structure of the lipooligosaccharide of Neisseria meningitidis: capacity of strain NMB to express all known immunotype epitopes. Glycobiology (2005) 15(4):409–419.
   PubMed Web of Science ®Google Scholar
• CHARALAMBOUS BM, FEAVERS IM: Peptide mimics elicit antibody responses against the outer-membrane lipooligosaccharide of group B Neisseria meningitidis. FEMS Microbiol Lett. (2000) 191(1):45–50.
   PubMed Web of Science ®Google Scholar
• JESSOUROUN E, DA SILVEIRA IF, LARANGEIRA AP et al: Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock. Vaccine (2004) 22(20):2617–2625.
   PubMed Web of Science ®Google Scholar
• POLLARD AJ, GALASSINI R, VAN DER VOORT EM et al: Humoral immune responses to Neisseria meningitidis in children. Infect. Immun. (1999) 67(5):2441–2451.
   PubMed Web of Science ®Google Scholar
• FISSEHA M, CHEN P, BRANDT B et al.: Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect. Immun. (2005) 73(7):4070–4080.
   PubMed Web of Science ®Google Scholar
• PARKHILL J, ACHTMAN M, JAMES KD et al.: Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature (2000) 404(6777):502–506.
   PubMed Web of Science ®Google Scholar
• TETTELIN H, SAUNDERS NJ, HEIDELBERG J et al.: Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science (2000) 287(5459):1809–1815.
   PubMed Web of Science ®Google Scholar
• PIZZA M, SCARLATO MASIGNANI Vet al.: Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science (2000) 287(5459):1816–1820.
   Google Scholar
• GRANOFF DM, MOE GR, GIULIANI MM et al.: A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis. J. Immunol. (2001) 167(10:6487–6496.
   PubMedGoogle Scholar
• ADU-BOBIE J, LUPETTI P, BRUNELLI B et al.: GNA33 of Neisseria meningitidis is a lipoprotein required for cell separation, membrane architecture, and virulence. Infect. Immun. (2004) 72(4):1914–1919.
   PubMed Web of Science ®Google Scholar
• MASIGNANI V, COMANDUCCI M, GIULIANI MM et al.: Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870.1 Exp. Med. (2003) 197(0:789–799.
   Google Scholar
• WELSCH JA, ROSSI R, COMANDUCCI M, GRANOFF DM: Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. Immunol. (2004) 172(9):5606–5615.
   Web of Science ®Google Scholar
• GIULIANI MM, SANTINI L, BRUNELLI B et al.: The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect. Immun. (2005) 73(2):1151–1160.
   PubMed Web of Science ®Google Scholar
• HOU VC, KOEBERLING O, WELSCH JA, GRANOFF DM: Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870.1 Infect. Dis. (2005) 192(4):580–590.
   Google Scholar
• FLETCHER LD, BERNFIELD L, BARNIAK Vet al.: Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. ?Immun. (2004) 72(4):2088–2100.
   Google Scholar
• COMANDUCCI M, BAMBINI S, BRUNELLI B et al.: NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med. (2002) 195(11):1445–1454.
   PubMed Web of Science ®Google Scholar
• CAPECCHI B, ADU-BOBIE J, DI MARCELLO F et al.: Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol. Microbiol. (2005) 55(3):687–698.
   Google Scholar
• LITT DJ, SAVINO S, BEDDEK A et al.: Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J. Infect. Dis. (2004) 190(8):1488–1497.
   PubMed Web of Science ®Google Scholar
• BOWE F, LAVELLE EC, MCNEELA EA et al.: Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin. Infect. Immun. (2004) 72(7):4052–4060.
   PubMed Web of Science ®Google Scholar
• SUN YH, BAKSHI S, CHALMERS R, TANG CM: Functional genomics of Neisseria meningitidis pathogenesis. Nat. Med. (2000) 6(11):1269–1273.
   PubMed Web of Science ®Google Scholar
• GRIFANTINI R, BARTOLINI E, MUZZI A et al.: Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat. Biotechnol (2002) 20(9):914–921.
   PubMed Web of Science ®Google Scholar
• YERO CD, PAJON FR, CABALLERO ME et al.: Immunization of mice with Neisseria meningitidis serogroup B genomic expression libraries elicits functional antibodies and reduces the level of bacteremia in an infant rat infectionmodel. Vaccine (2005) 23(7):932–939.
   PubMed Web of Science ®Google Scholar
• JOHNSON CR, NEWCOMBE J, THORNE S et al.: Generation and characterization of a PhoP homologue mutant of Neisseria meningitidis. Mol Microbiol (2001) 39(5):1345–1355.
   PubMed Web of Science ®Google Scholar
• NEWCOMBE J, EALES-REYNOLDS LJ, WOOTTON Let al.: Infection with an avirulent phoP mutant of Neisseria meningitidis confers broad cross-reactive immunity. Infect. Immun. (2004) 72(1):338–344.
   Google Scholar
• LI Y, SUN YH, ISON C, LEVINE MM, TANG CM: Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live meningococci. Infect. Immun. (2004) 72(0:345–351.
   PubMedGoogle Scholar
• BILLE E, ZAHAR JR, PERRIN A et al.: A chromosomally integrated bacteriophage in invasive meningococci. 1 Exp. Med. (2005) 201(12):1905–1913. Websites
   Google Scholar
• http://www.moh.govt.nz/moh.nsf/0/ CO 88F437895D6DC8CC256ED1000B25 39/$File/ epidemiologyofmeningococcaldisease2003. Pdf The epidemiology of meningococcal disease in New Zealand in 2003. New Zealand Ministry of Health Publications, July 2004.
   Google Scholar
• http://www.immunise.moh.govt.nz/ documents/6weeksgpletter.pdf MeNZBTm vaccination licence extended to infants aged 6 weeks to 5 months. New Zealand Ministry of Health Publications, February 2005.
   Google Scholar